Cellebrite DI Ltd (CLBT) Fair Value & Analysis
Technology · US · Market cap $3.7B
Fair value as of: Jun 24, 2026
Analysis
Cellebrite DI Ltd (CLBT) currently trades at $12.74, while our model-based Fair Value estimate is $5.21 — implying the stock looks roughly 59.1% overvalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digi…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Cellebrite DI Ltd (CLBT) undervalued?
What is the fair value of CLBT?
What is the quality score of CLBT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.